OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
Ann Murray, Jennifer I. Stern, Carrie E. Robertson, et al.
Current Pain and Headache Reports (2022) Vol. 26, Iss. 10, pp. 783-794
Closed Access | Times Cited: 21
Ann Murray, Jennifer I. Stern, Carrie E. Robertson, et al.
Current Pain and Headache Reports (2022) Vol. 26, Iss. 10, pp. 783-794
Closed Access | Times Cited: 21
Showing 21 citing articles:
Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
Andrew Charles, Kathleen B. Digre, Peter J. Goadsby, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 4, pp. 333-341
Open Access | Times Cited: 65
Andrew Charles, Kathleen B. Digre, Peter J. Goadsby, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 4, pp. 333-341
Open Access | Times Cited: 65
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 41
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 41
Health equity, care access and quality in headache – part 2
Bianca Raffaelli, Eloísa Rubio‐Beltrán, Soo‐Jin Cho, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 25
Bianca Raffaelli, Eloísa Rubio‐Beltrán, Soo‐Jin Cho, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 25
Medication “underuse” headache
Wanakorn Rattanawong, Alan M. Rapoport, Anan Srikiatkhachorn
Cephalalgia (2024) Vol. 44, Iss. 4
Open Access | Times Cited: 9
Wanakorn Rattanawong, Alan M. Rapoport, Anan Srikiatkhachorn
Cephalalgia (2024) Vol. 44, Iss. 4
Open Access | Times Cited: 9
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 5, pp. 1435-1442
Closed Access | Times Cited: 17
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 5, pp. 1435-1442
Closed Access | Times Cited: 17
Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies – insights from the German NeuroTransData registry
Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Altered immunity in migraine: a comprehensive scoping review
Woo-Seok Ha, Min Kyung Chu
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Woo-Seok Ha, Min Kyung Chu
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311776-033310242311776
Open Access | Times Cited: 15
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311776-033310242311776
Open Access | Times Cited: 15
Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims Study
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Patient Preference and Adherence (2025) Vol. Volume 19, pp. 543-567
Open Access
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Patient Preference and Adherence (2025) Vol. Volume 19, pp. 543-567
Open Access
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Hellenic Headache Society Recommendations for the Use of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide Pathway for the Prevention of Migraine and Cluster Headache—2023 Update
Dimos D. Mitsikostas, A. Alexoudi, Chrysa Arvaniti, et al.
SN Comprehensive Clinical Medicine (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 9
Dimos D. Mitsikostas, A. Alexoudi, Chrysa Arvaniti, et al.
SN Comprehensive Clinical Medicine (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 9
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Currently Available Interventions for the Management of Migraine Pain
Rakesh K. Singh, Shivam Kumar Pandey, Shreya Singh, et al.
(2024), pp. 191-227
Closed Access | Times Cited: 2
Rakesh K. Singh, Shivam Kumar Pandey, Shreya Singh, et al.
(2024), pp. 191-227
Closed Access | Times Cited: 2
One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
Michel Lantéri‐Minet, R. Fabre, Caroline Martin, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Michel Lantéri‐Minet, R. Fabre, Caroline Martin, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clinical and genetic study
Bruce A. Chase, Irene Semenov, Susan Rubin, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 64, Iss. 1, pp. 68-92
Open Access | Times Cited: 6
Bruce A. Chase, Irene Semenov, Susan Rubin, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 64, Iss. 1, pp. 68-92
Open Access | Times Cited: 6
The pharmacotherapeutic management of episodic and chronic migraine with gepants
János Tajti, Délia Szok, Anett Csáti, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 8, pp. 947-958
Open Access | Times Cited: 4
János Tajti, Délia Szok, Anett Csáti, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 8, pp. 947-958
Open Access | Times Cited: 4
Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine
Amira Salim, Sudipa Biswas, Claire Sonneborn, et al.
Neurology Clinical Practice (2024) Vol. 15, Iss. 1
Closed Access | Times Cited: 1
Amira Salim, Sudipa Biswas, Claire Sonneborn, et al.
Neurology Clinical Practice (2024) Vol. 15, Iss. 1
Closed Access | Times Cited: 1
Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study
Paul Triller, Virginia N. Blessing, Lucas Hendrik Overeem, et al.
Cephalalgia (2024) Vol. 44, Iss. 10
Closed Access | Times Cited: 1
Paul Triller, Virginia N. Blessing, Lucas Hendrik Overeem, et al.
Cephalalgia (2024) Vol. 44, Iss. 10
Closed Access | Times Cited: 1
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review
Tsubasa Takizawa, Keiko Ihara, Shunsuke Uno, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 951-967
Closed Access | Times Cited: 3
Tsubasa Takizawa, Keiko Ihara, Shunsuke Uno, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 951-967
Closed Access | Times Cited: 3
Fremanezumab in real-life clinical practice: specialized headache center experience
Yu. É. Azimova, K. V. Skorobogatikh, V. В. Osipova, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 3, pp. 72-78
Open Access
Yu. É. Azimova, K. V. Skorobogatikh, V. В. Osipova, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 3, pp. 72-78
Open Access
